Anticoagulation plans prior to TURP, from Kavanagh 2011
Medications that decrease bleeding during TURP, from Kavanagh 2011
mTURP | bTURP | TUNA | TUMT | HoLEP | PVP | TUVP | TUIP | |
---|---|---|---|---|---|---|---|---|
Temporary retention | 4.3-6.8% | 3.3-3.7% | 23% | 10-24% | 2.7-5.9% | 5.2-9.9% | 2-9.8% | 4.9-11.3% |
UTI | 4.1-6.2% | 2.6-8.4% | 4% | 15-20% | 0.9-2.7% | 4.2-12% | 0% | - |
BNC | 2-3.2% | 0.5% | - | 0% | 1.2-1.5% | 1.1-5% | 0.5-1% | - |
Stricture | 3.4-4.1% | 0.5-4.7% | 0.5% | 0-2% | 1.9-4.4% | 1-6.3% | 1.9-3.3% | 2.9-8.8% |
Incontinence | 0.6-1.5% | 0-1% | - | - | 0.9-1.1% | 0-0.4% | 0-2% | 0.3-1.8% |
Transfusion | 2-4.4% | 1.5-2.3% | rare | 0% | 0-1% | 0% | 0-0.5% | 1.1% |
Clot retention | 4.9-7.2% | 2.7-7.9% | - | 1% | 0% | 0% | 0-0.5% | - |
Hematuria | 3.5-15.7% | 1% | 6-28% | 1-26% | 0% | 0.7% | 0% | 4.3% |
Dysuria | 0.8% | 0% | 8-14% | 14% | 1.2% | 8.5-13.9% | 2.9% | - |
Urgency | 2.2% | 0.2% | 10% | - | 5.6% | 0% | 0% | - |
Storage symptoms | - | - | - | 18-31% | - | - | 21% | - |
Reoperation for BPE | 0.5% | 0.2% | 19% | 4% | 0% | 0.7-5.6% | 2.4% | - |
Reoperation other than for BPE | 1.1% | 0.2% | 0% | - | 1.9-2.8% | - | 5.4% | 9.6-18.4% |
Capsular perforation | 0.1% | 0% | - | - | 0.2% | 0% | 0% | - |
Conversion to TURP | n/a | 0% | n/a | n/a | 0% | 3.5% | 0% | - |
TUR syndrome | 0.8-2.5% | 0% | 0% | 0% | 0% | 0% | 0% | - |
Bladder mucosal injury | 0% | 0% | 0% | - | 3.3% | 0% | 0% | - |